3 Citations (Scopus)

Abstract

Transfusion of red blood cells, platelets and plasma is widely used in the management of anemia and coagulopathy in cancer patients undergoing surgery, chemotherapy, and radiation. The decision to transfuse should not be made lightly as exposure to transfused blood, whether from an allogeneic or even autologous source, is not without risk and the long-term effect of blood transfusion on cancer outcomes remains questionable. Recognition of anemia associated with nutritional deficiency should be promptly corrected while avoiding the use of erythropoiesis stimulating agents. Minimizing blood loss and the prompt control of bleeding, coupled with a restrictive transfusion strategy, seem to be a reasonable approach that does not appear to be associated with long-term sequelae. Limiting platelet transfusion to patients with severe hypo-proliferative thrombocytopenia, and implementation of local hemostatic measures, together with the use of fractionated coagulation factor concentrates, as an alternative to frozen plasma transfusion, may reduce the exposure of cancer patients to potentially harmful thrombogenic and pro-inflammatory cellular microparticles. This joint narrative highlights current opinions for minimizing blood usage in patients with cancer.

Original languageEnglish
Pages (from-to)322-329
Number of pages8
JournalTransfusion and Apheresis Science
Volume56
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Joints
Anemia
Neoplasms
Hematinics
Platelet Transfusion
Blood Coagulation Factors
Hemostatics
Malnutrition
Blood Transfusion
Thrombocytopenia
Blood Platelets
Erythrocytes
Radiation
Hemorrhage
Drug Therapy

Keywords

  • Alternatives
  • Cancer
  • Reduction
  • Transfusion

ASJC Scopus subject areas

  • Hematology

Cite this

Reflections on multiple strategies to reduce transfusion in cancer patients : A joint narrative. / Goubran, Hadi Alphonse; Seghatchian, Jerard; Prokopchuk-Gauk, Oksana; Radosevic, Julia; Sabry, Waleed; Iqbal, Nayyer; Burnouf, Thierry.

In: Transfusion and Apheresis Science, Vol. 56, No. 3, 2017, p. 322-329.

Research output: Contribution to journalArticle

Goubran, Hadi Alphonse ; Seghatchian, Jerard ; Prokopchuk-Gauk, Oksana ; Radosevic, Julia ; Sabry, Waleed ; Iqbal, Nayyer ; Burnouf, Thierry. / Reflections on multiple strategies to reduce transfusion in cancer patients : A joint narrative. In: Transfusion and Apheresis Science. 2017 ; Vol. 56, No. 3. pp. 322-329.
@article{24964f53291e48fcb464c3bd4c027bc0,
title = "Reflections on multiple strategies to reduce transfusion in cancer patients: A joint narrative",
abstract = "Transfusion of red blood cells, platelets and plasma is widely used in the management of anemia and coagulopathy in cancer patients undergoing surgery, chemotherapy, and radiation. The decision to transfuse should not be made lightly as exposure to transfused blood, whether from an allogeneic or even autologous source, is not without risk and the long-term effect of blood transfusion on cancer outcomes remains questionable. Recognition of anemia associated with nutritional deficiency should be promptly corrected while avoiding the use of erythropoiesis stimulating agents. Minimizing blood loss and the prompt control of bleeding, coupled with a restrictive transfusion strategy, seem to be a reasonable approach that does not appear to be associated with long-term sequelae. Limiting platelet transfusion to patients with severe hypo-proliferative thrombocytopenia, and implementation of local hemostatic measures, together with the use of fractionated coagulation factor concentrates, as an alternative to frozen plasma transfusion, may reduce the exposure of cancer patients to potentially harmful thrombogenic and pro-inflammatory cellular microparticles. This joint narrative highlights current opinions for minimizing blood usage in patients with cancer.",
keywords = "Alternatives, Cancer, Reduction, Transfusion",
author = "Goubran, {Hadi Alphonse} and Jerard Seghatchian and Oksana Prokopchuk-Gauk and Julia Radosevic and Waleed Sabry and Nayyer Iqbal and Thierry Burnouf",
year = "2017",
doi = "10.1016/j.transci.2017.05.018",
language = "English",
volume = "56",
pages = "322--329",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Reflections on multiple strategies to reduce transfusion in cancer patients

T2 - A joint narrative

AU - Goubran, Hadi Alphonse

AU - Seghatchian, Jerard

AU - Prokopchuk-Gauk, Oksana

AU - Radosevic, Julia

AU - Sabry, Waleed

AU - Iqbal, Nayyer

AU - Burnouf, Thierry

PY - 2017

Y1 - 2017

N2 - Transfusion of red blood cells, platelets and plasma is widely used in the management of anemia and coagulopathy in cancer patients undergoing surgery, chemotherapy, and radiation. The decision to transfuse should not be made lightly as exposure to transfused blood, whether from an allogeneic or even autologous source, is not without risk and the long-term effect of blood transfusion on cancer outcomes remains questionable. Recognition of anemia associated with nutritional deficiency should be promptly corrected while avoiding the use of erythropoiesis stimulating agents. Minimizing blood loss and the prompt control of bleeding, coupled with a restrictive transfusion strategy, seem to be a reasonable approach that does not appear to be associated with long-term sequelae. Limiting platelet transfusion to patients with severe hypo-proliferative thrombocytopenia, and implementation of local hemostatic measures, together with the use of fractionated coagulation factor concentrates, as an alternative to frozen plasma transfusion, may reduce the exposure of cancer patients to potentially harmful thrombogenic and pro-inflammatory cellular microparticles. This joint narrative highlights current opinions for minimizing blood usage in patients with cancer.

AB - Transfusion of red blood cells, platelets and plasma is widely used in the management of anemia and coagulopathy in cancer patients undergoing surgery, chemotherapy, and radiation. The decision to transfuse should not be made lightly as exposure to transfused blood, whether from an allogeneic or even autologous source, is not without risk and the long-term effect of blood transfusion on cancer outcomes remains questionable. Recognition of anemia associated with nutritional deficiency should be promptly corrected while avoiding the use of erythropoiesis stimulating agents. Minimizing blood loss and the prompt control of bleeding, coupled with a restrictive transfusion strategy, seem to be a reasonable approach that does not appear to be associated with long-term sequelae. Limiting platelet transfusion to patients with severe hypo-proliferative thrombocytopenia, and implementation of local hemostatic measures, together with the use of fractionated coagulation factor concentrates, as an alternative to frozen plasma transfusion, may reduce the exposure of cancer patients to potentially harmful thrombogenic and pro-inflammatory cellular microparticles. This joint narrative highlights current opinions for minimizing blood usage in patients with cancer.

KW - Alternatives

KW - Cancer

KW - Reduction

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=85021196150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021196150&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2017.05.018

DO - 10.1016/j.transci.2017.05.018

M3 - Article

VL - 56

SP - 322

EP - 329

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -